DASH
Repository logo
Communities & Collections
Browse DASH
DASH Stories
Statistics
  1. Home
  2. Faculty of Arts and Sciences
  3. FAS Theses and Dissertations
  4. Precision Medicine: Biomarkers of Genome Integrity in Guiding Better Lung Cancer Outcomes

Precision Medicine: Biomarkers of Genome Integrity in Guiding Better Lung Cancer Outcomes

Open/View files
TingZhai.PHS.EH.Dissertation.combined.pdf (14.35 MB)
Date
January 5, 2026
Author(s)
Zhai, Ting
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Zhai, Ting. 2026. Precision Medicine: Biomarkers of Genome Integrity in Guiding Better Lung Cancer Outcomes. Doctoral Dissertation, Harvard University Graduate School of Arts and Sciences.
Abstract
Lung cancer remains the leading cause of cancer mortality, and standard treatments such as radiotherapy (RT) and chemotherapy act through DNA damage. Yet patients show substantial variability in both treatment response and side effects. Because DNA repair is central to maintaining genome integrity and differs across individuals and life stages, assessing genome integrity could help identify which patients will benefit most from therapy while minimizing harmful outcomes. My dissertation focuses on developing and applying genome-integrity biomarkers to better understand treatment response and prognosis in lung cancer. I focused on three complementary domains: functional DNA repair capacity measured by fluorescence multiplex host cell reactivation (FM-HCR), telomere length dynamics during and after RT, and germline genetic variation. Across this work, I established strategies to adapt functional DNA repair assays for population studies, demonstrating that they capture meaningful inter-individual differences. I showed that changes in telomere length over the course of treatment provide stronger signals for predicting side effects than single, static measurements. And by integrating genetic data with functional measures, I found that certain genetic variants influence repair capacity and contribute to differences in treatment toxicity and prognosis. Together, these studies highlight the value of linking functional and genomic measures of genome integrity. By bringing these approaches together, my work provides a framework for using genome-integrity biomarkers to guide more personalized RT decisions and improve long-term outcomes in lung cancer patients.
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service
URI
https://dash.harvard.edu/handle/1/42731176
Subjects

DNA repair

Genome integrity

Lung cancer

Molecular epidemiolog...

Precision medicine

Radiotherapy

Epidemiology

Environmental health

Health sciences

Collection
FAS Theses and Dissertations
Metrics
Repository logo
  • CONTACT US
  • OSRDS
  • ABOUT DASH
  • DEPOSITING TO DASH
  • TERMS OF USE
  • REQUEST A WAIVER
  • TAKE DOWN POLICY
  • NAME CHANGE POLICY
  • HARVARD OA POLICIES
  • DASH SUBMITTER AGREEMENT
  • Accessibility
  • Privacy
Creative Commons License BY
Creative Commons Attribution 4.0 International License

Except where otherwise noted, this work is subject to a Creative Commons Attribution 4.0 International License,
which allows anyone to share and adapt our material as long as proper attribution is given.
For details and exceptions, see the Harvard Library Copyright Policy
©2024 Presidents and Fellows of Harvard College.